meta
|
evidence
oncology
Living systematic review and meta-analysis
multiple myeloma - 2nd line (L2)
1
myofibroblastic tumors
neurofibroma
neutropenia
new pathology
osteosarcoma
ovarian cancer (OC)
9
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel
atezolizumab plus SoC
avelumab based treatment
avelumab alone
avelumab plus pegylated liposomal doxorubicin
avelumab plus SoC
nivolumab based treatment
Immune checkpoint association
nivolumab plus ipilimumab
poly ADP-ribose polymerase (PARP) inhibitor
niraparib
olaparib
rucaparib
target therapy
multikinase inhibitor
nintedanib
versus all
vs chemotherapy
vs non platinum-based chemotherapy
vs anthracyclines
vs doxorubicin
vs pegylated liposomal doxorubicin
vs Standard of Care (SoC)
vs placebo plus SoC
vs immune chekpoint inhibitors
vs anti-PD-(L)1
vs nivolumab based treatment
vs nivolumab alone
vs poly ADP-ribose polymerase (PARP) inhibitor
vs rucaparib
vs VEGF(R) inhibitor
vs bevacizumab based treatment
vs bevacizumab plus carboplatin and paclitaxel
All patients
Age < 65y (younger)
Age > 65y
Asian type
ECOG ⩾ 1
ECOG 0
ECOG 1
hemoglobin concentration > 10g/dl
PD-L1 < 1%
PD-L1 > 1%
PDL1 (TC0 and IC0 : <1% of TC and IC)
PDL1 (TC1/2 or IC1/2 : ≥1% of TC or IC and <50% of TC and <10% of IC)
PDL1 (TC2/3 or IC2/3 : ≥5% of TC or IC)
stage III (locally advanced)
stage IV (metastatic)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
DCR
deaths (OS)
DOR
objective responses (ORR)
PFS (extension)
progression or deaths (PFS)
AE (any grade)
AE (grade 3-4)
AE leading to death (grade 5)
AE leading to treatment discontinuation (any grade)
SAE (any grade)
STRAE (any grade)
TRAE (any grade)
TRAE (grade 3-4)
TRAE leading to death (grade 5)
TRAE leading to discontinuation (any grade)
Abdominal pain TRAE (grade 3-4)
Acute kidney injury TRAE (grade 3-4)
Adrenal insufficiency TRAE (grade 3-4)
Anaemia TRAE (grade 3-4)
Arthritis TRAE (grade 3-4)
Asthenia TRAE (grade 3-4)
Blood creatinine increased TRAE (grade 3-4)
Colitis TRAE (grade 3-4)
Constipation TRAE (grade 3-4)
Decreased appetite TRAE (grade 3-4)
Diabetes TRAE (grade 3-4)
Diarrhoea TRAE (grade 3-4)
Dry skin TRAE (grade 3-4)
Dyspnoea TRAE (grade 3-4)
Fatigue TRAE (grade 3-4)
Febrile neutropenia TRAE (grade 3-4)
Guillain-Barré syndrome TRAE (grade 3-4)
Hepatitis TRAE (grade 3-4)
Hypersensitivity TRAE (grade 3-4)
Hypertension TRAE (grade 3-4)
Hyperthyroidism TRAE (grade 3-4)
Hypothyroidism TRAE (grade 3-4)
Increase AST TRAE (grade 3-4)
Increased ALT TRAE (grade 3-4)
Increased lipase level TRAE (grade 3-4)
Infusion-related reactions TRAE (grade 3-4)
Leucopenia TRAE (grade 3-4)
Maculopapular rash TRAE (grade 3-4)
Mucosal inflammation TRAE (grade 3-4)
Myocarditis TRAE (grade 3-4)
Myositis TRAE (grade 3-4)
Nausea TRAE (grade 3-4)
Nephritis TRAE (grade 3-4)
Neutropenia TRAE (grade 3-4)
Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4)
Pancreatitis TRAE (grade 3-4)
Pancytopenia TRAE (grade 3-4)
Peripheral neuropathy TRAE (grade 3-4)
Peripheral oedema TRAE (grade 3-4)
Pneumonia TRAE (grade 3-4)
Pneumonitis TRAE (grade 3-4)
Pruritic rash TRAE (grade 3-4)
Pruritus TRAE (grade 3-4)
Pyrexia TRAE (grade 3-4)
Rash TRAE (grade 3-4)
Sepsis TRAE (grade 3-4)
Severe skin reaction TRAE (grade 3-4)
Skin exfoliation TRAE (grade 3-4)
Stomatitis TRAE (grade 3-4)
Thrombocytopenia TRAE (grade 3-4)
Vomiting TRAE (grade 3-4)
Acute kidney injury AE (grade 3-4)
Decreased appetite AE (grade 3-4)
Dyspnoea AE (grade 3-4)
Hypertension AE (grade 3-4)
Infusion-related reaction AE (grade 3-4)
Proteinuria AE (grade 3-4)
DCR
ovarian cancer (OC)
ovarian cancer (OC)
versus bevacizumab plus carboplatin and paclitaxel
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel vs. bevacizumab plus carboplatin and paclitaxel
1
-
metastatic/advanced OC (mOC) - 1st line (L1)
metastatic/advanced OC (mOC) - 1st line (L1)
versus bevacizumab plus carboplatin and paclitaxel
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel vs. bevacizumab plus carboplatin and paclitaxel
1
-
mOC - L1 - all population
metastatic/advanced OC (mOC) - 1st line (L1)
mOC - L1 - all population
versus placebo plus SoC
atezolizumab plus SoC vs. placebo plus SoC
1
-
mOC - L1 - PDL1 positive
metastatic/advanced OC (mOC) - 1st line (L1)
mOC - L1 - PDL1 positive
versus placebo plus SoC
atezolizumab plus SoC vs. placebo plus SoC
1
-
metastatic/advanced OC (mOC) - 2nd line (L2)
metastatic/advanced OC (mOC) - 2nd line (L2)
versus nivolumab alone
nivolumab plus ipilimumab vs. nivolumab alone
1
-
versus pegylated liposomal doxorubicin
avelumab alone vs. pegylated liposomal doxorubicin
1
certainty unassessable
+102%
avelumab plus pegylated liposomal doxorubicin vs. pegylated liposomal doxorubicin
1
certainty unassessable
+179%
metastatic/advanced OC (mOC) - maintenance (M)
metastatic/advanced OC (mOC) - maintenance (M)
versus rucaparib
nivolumab based treatment vs. rucaparib
1
-
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open